PD-L1 expression shows potential utility in predicting malignant transformation risk in oral potentially malignant disordersPD-L1 expression may help identify risk in oral pre-cancer

This systematic review and meta-analysis evaluated the role of immune checkpoint proteins, specifically PD-L1 and another unspecified immune checkpoint protein (ICP), in patients with oral potentially malignant disorders (OPMDs). The study included a total population of 613 patients to assess whether these markers could serve as indicators for clinical progression.

The primary objective was to evaluate the ability of these biomarkers to predict the risk of malignant transformation (MT) in patients presenting with OPMDs. The analysis focused on identifying specific patterns of expression that correlate with higher risks of progression to oral cancer, which is a critical concern in managing high-risk lesions.

Regarding the primary outcome, the study reported a malignant transformation rate of 21.04% among the included patients, representing 129 out of 613 cases. The analysis specifically looked at PD-L1 utility in predicting MT risk and concluded that it was identified as having potential utility. However, no specific p-values or confidence intervals were provided for these primary findings.

Secondary outcomes focused on the specific utility of PD-L1 in predicting MT risk. While the review noted potential utility, the evidence base is described as fragmented. The study did not provide specific data points for other immune checkpoint proteins beyond the initial identification of their presence and potential roles.

Safety and tolerability data were not reported in this analysis, as it was a meta-analysis of biomarker expression rather than an interventional trial. No adverse events or discontinuation rates were documented.

These findings contribute to the broader understanding of molecular markers in oral oncology. While previous research has established that molecular markers may improve risk assessment in OPMDs and that transcriptomic shifts are associated with immune cell enrichment during dysplasia progression, this specific analysis focuses on the predictive value of PD-L1 as a standalone or primary marker.

Several methodological limitations were noted, including fragmented evidence and a lack of clinical evidence regarding other ICPs. Furthermore, the actual clinical utility of PD-L1 in a routine diagnostic setting remains unestablished at this time. The study notes that while an association between PD-L1 expression and MT risk is observed as potential utility, no direct causation has been established.

Clinically, elucidating the roles of immune checkpoint proteins (ICPs) in OPMDs could eventually enable more precise risk stratification and immunopreventive strategies. This may facilitate earlier intervention and potentially reduce the incidence of oral cancer. However, clinicians should note that the evidence is currently insufficient to base routine clinical decisions solely on PD-L1 expression.

Several questions remain unanswered regarding the specific thresholds for PD-L1 expression that correlate with high risk, the roles of other ICPs in OPMDs, and how these markers perform in diverse patient populations. Further investigation is required to establish the definitive clinical application of PD-L1 in the management of oral potentially malignant disorders.